Cost Drivers in Patients with Classic Congenital Adrenal Hyperplasia (CAH)

MFarrar , C O’Donoghue , E Paiewonsky , C Yonan , R Nathan , D Pfeffer , V Tiwari , P Shripathi , P Russo

Abstract

Classic CAH is a rare condition characterized by cortisol deficiency and androgen excess, typically requiring treatment with supraphysiologic doses of glucocorticoids. This study evaluated the costs and identified key cost drivers for classic CAH in the United States (US).

More Publications

Omalizumab for IgE-mediated food allergy: A systematic review and meta-analysis

Zuberbier T , Wood RA , Bindslev-Jensen C , Fiocchi A , Chinthrajah S , Worm M , Deschildre A , Rivas MF , Santos A , Jaumont JX , Tassinari P

Dec, 2022

The Journal of Allergy and Clinical Immunology: In Practice

Efficacy and safety of bisoprolol compared to other selective beta-1 blockers in the treatment of hypertension: a systematic review and meta-analysis of randomized parallel clinical trials

U Jadhav , T Nair , S Bansal , S Ray

Oct, 2021

European Heart Journal

Effect of omalizumab on glucocorticoid use and lung function in the treatment of allergic bronchopulmonary aspergillosis in people with cystic fibrosis: a systematic review and meta-analysis

Meiling Jin , Jo A. Douglass , J. Stuart Elborn , Slawomir Lazarewicz , Xavier Jaumont , Meng Yan , Ritesh Agarwal, , William J. Calhoun,

Dec, 2022

The Journal of Allergy and Clinical Immunology